|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | On the worst-case disturbance of minimax optimal control 显示文摘 | Myung Y Valery U Ian P | 2005 | Autornatica2005，41，5： | 1 |
| 2 | On the worst-case disturbance of minimax optimal control显示文摘 | Myung Y Valery U Ian P | 2005 | Automatica2005，41，5： | 1 |
| 3 | Therapeutic uses of somatostatin and its analogues:Current view and potential applications显示文摘 | Rai U Thrimawithana TR Valery C | 2015 | Pharmacol Ther2015，152，： | 1 |
| 4 | Therapeutic uses of somatostatin and its analogues: Current view and potential applications显示文摘 | Rai U Thrimawithana TR Valery C | 2015 | Pharmacol Ther2015，152，： | 1 |
| 5 | Can we measure snow depth with GPS receivers?显示文摘 | KRISTINE M L ETHAN D G VALERY U Z | 2009 | Geophysical Research Letters2009，36，17： | 1 |
| 6 | Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis显示文摘AIM To investigate the impact of medication beliefs, illness perceptions and quality of life on medication adherence in people with decompensated cirrhosis.METHODS One hundred adults with decompensated cirrhosis completed a structured questionnaire when they attended for routine outpatient hepatology review. Measures of self-reported medication adherence(Morisky Medication Adherence Scale), beliefs surrounding medications(Beliefs about Medicines Questionnaire), perceptions of illness and medicines(Brief Illness Perception Questionnaire), and quality of life(Chronic Liver Disease Questionnaire) were examined. Clinical data were obtained via patient history and review of medical records. Least absolute shrinkage and selection operator and stepwise backwards regression techniques were used to construct the multivariable logistic regression model. Statistical significance was set at alpha = 0.05.RESULTS Medication adherence was ' High ' in 42 % o f participants, 'Medium' in 37%, and 'Low' in 21%. Compared to patients with 'High' adherence, those with 'Medium' or 'Low' adherence were more likely to report difficulty affording their medications(P < 0.001), lower perception of treatment helpfulness(P = 0.003) and stronger medication concerns relative to medication necessity beliefs(P = 0.003). People with 'Low' adherence also experienced greater symptom burden and poorer quality of life, including more frequent abdominal pain(P = 0.023), shortness of breath(P = 0.030), and emotional disturbances(P = 0.050). Multivariable analysis identified having stronger medication concerns relative to necessity beliefs(Necessity-Concerns Differential ≤ 5, OR = 3.66, 95%CI: 1.18-11.40) and more frequent shortness of breath(shortness of breath score ≤ 3, OR = 3.87,95%CI: 1.22-12.25) as independent predictors of 'Low'adherence.CONCLUSION The association between 'Low' adherence and patients having strong concerns or doubting the necessity or helpfulness of their medications should be explored further given the clinical relevance. | Kelly L Hayward Patricia C Valery Jennifer H Martin Antara Karmakar Preya J Patel Leigh U Horsfall Caroline J Tallis Katherine A Stuart Penny L Wright David D Smith Katharine M Irvine Elizabeth E Powell W Neil Cottrell | 2017 | World Journal of Gastroenterology2017，23，40： | 1 |
| 7 | 显示文摘 | Valeri S Altieri S del Pennino U | 2002 | Phys Rev B2002，65，24： | 1 |
| 8 | CD34^+ leukemic subpopulation predominantly displays lower spontaneous apoptosis and has higher expression levels of Bcl - 2 and MDR1 genes than CD34 - cells in childhood AML 显示文摘 | Tatsiana V Shman Uladzimir U Fedasenka Valery | 2008 | Ann Hematol2008，87，： | 1 |
| 9 | Can we measure snow depth with GPS receivers?显示文摘 | KRISTINE M L ETHAN D G VALERY U Z | 2009 | Geophysical Research Letters2009，36，17： | 1 |
| 10 | Study on thermal decomposition and combustion of insensitive显示文摘 | Valery Sinditskll Mania Cuong V U Vera S | 1995 | Propellants Explosives Pyrotechnics1995，3，： | 1 |
| 11 | 显示文摘 | Valeri S Altieri S del Pennino U | 2002 | Phys Rev B2002，65，24： | 1 |
| 12 | Guaranteed cost control of uncertain systems via Lur' e-Postnikov Lyapunov functions 显示文摘 | IAN R P | 2000 | Automatica2000，36，2： | 1 |
| 13 | Factors associated with success of telaprevir-and boceprevir-based triple therapy for hepatitis C virus infection显示文摘AIM To evaluate new therapies for hepatitis C virus(HCV), data about real-world outcomes are needed.METHODS Outcomes of 223 patients with genotype 1 HCV who started telaprevir-or boceprevir-based triple therapy(May 2011-March 2012) at the Mount Sinai Medical Center were analyzed. Human immunodeficiency viruspositive patients and patients who received a liver transplant were excluded. Factors associated with sustained virological response(SVR24) and relapse were analyzed by univariable and multivariable logistic regression as well as classification and regression trees. Fast virological response(FVR) was defined as undetectable HCV RNA at week-4(telaprevir) or week-8(boceprevir). RESULTS The median age was 57 years, 18% were black, 44% had advanced fibrosis/cirrhosis(FIB-4 ≥ 3.25). Only 42%(94/223) of patients achieved SVR24 on an intention-totreat basis. In a model that included platelets, SVR24 was associated with white race [odds ratio(OR) = 5.92, 95% confidence interval(CI): 2.34-14.96], HCV sub-genotype 1b(OR = 2.81, 95%CI: 1.45-5.44), platelet count(OR = 1.10, per x 104 cells/μL, 95%CI: 1.05-1.16), and IL28 B CC genotype(OR = 3.54, 95%CI: 1.19-10.53). Platelet counts > 135 x 103/μL were the strongest predictor of SVR by classification and regression tree. Relapse occurred in 25%(27/104) of patients with an end-oftreatment response and was associated with non-FVR(OR = 4.77, 95%CI: 1.68-13.56), HCV sub-genotype 1a(OR = 5.20; 95%CI: 1.40-18.97), and FIB-4 ≥ 3.25(OR = 2.77; 95%CI: 1.07-7.22). CONCLUSION The SVR rate was 42% with telaprevir-or boceprevirbased triple therapy in real-world practice. Low platelets and advanced fibrosis were associated with treatment failure and relapse. | Kian Bichoupan Neeta Tandon Valerie Martel-Laferriere Neal M Patel David Sachs Michel Ng Emily A Schonfeld Alexis Pappas James Crismale Alicia Stivala Viktoriya Khaitova Donald Gardenier Michael Linderman William Olson Ponni V Perumalswami Thomas D Schiano Joseph A Odin Lawrence U Liu Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Hepatology2017，9，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员